Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Despite the prophylactic use of allopurinol, tumor lysis syndrome (TLS)-related morbidity and mortality still occur in a number of patients with acute myeloid leukemia (AML). The aim of this study was: (i) to analyze the incidence and outcome of TLS in a large series of patients with AML receiving hyperhydration and allopurinol, (ii) to identify risk factors for TLS, and (iii) to develop a prognostic scoring system for estimating individual risk of TLS. DESIGN AND METHODS: The study included 772 adult patients with AML receiving induction chemotherapy between 1980 and 2002. TLS was divided into laboratory TLS (LTLS) or clinical TLS (CTLS). The population study was randomly divided into training and test subsets, so that a prognostic model for CTLS was developed in one set and validated in the other. RESULTS: Overall, 130 patients (17%) developed TLS (5% CTLS and 12% LTLS). Unlike LTLS, CTLS was associated with a higher rate of death from induction therapy. Multivariate analysis showed that pretreatment serum lactate dehydrogenase (LDH) levels above laboratory normal values, creatinine >1.4 mg/dL, uric acid >7.5 mg/dL and white blood cell (WBC) counts >25 x 10(9)/L were independent risk factors for CTLS and LTLS. The scoring system, based on pretreatment WBC counts, and uric acid and LDH serum levels, had excellent discrimination and was accurate for predicting CTLS and LTLS. CONCLUSIONS: TLS is frequently observed in AML patients during induction therapy. Only the development of CTLS had an impact on higher mortality rate from induction therapy. The scoring system derived from this study can be used to obtain an accurate estimate of the individual risk of TLS, allowing for risk-adapted prophylaxis against this complication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
Cairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
How I treat acute myeloid leukemia in the era of new drugs
DiNardo, C. D., & Wei, A. H. (2020) · Blood · doi:10.1182/blood.2019001239 · Cited by 290
Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001511 · Cited by 282
Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge
Erbach, M., Freckmann, G., Hinzmann, R., Kulzer, B., Ziegler, R., Heinemann, L., & Schnell, O. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816641433 · Cited by 115
Metadata
- Authors
- Montesinos, P., Lorenzo, I., Martin, G., Sanz, J., Perez-Sirvent, M. L., Martinez, D., Orti, G., Algarra, L., Martinez, J., Moscardo, F., de la Rubia, J., Jarque, I., Sanz, G., & Sanz, M. A.
- Venue
- Haematologica
- Published
- 2008-01-01
- Volume
- 93
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2116061272
- Cited by
- 231
- References
- 0
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. https://app.cochat.ai/papers/10.3324/haematol.11575
- The paper
- Montesinos, P., Lorenzo, I., Martin, G., Sanz, J., Perez-Sirvent, M. L., Martinez, D., Orti, G., Algarra, L., Martinez, J., Moscardo, F., de la Rubia, J., Jarque, I., Sanz, G., & Sanz, M. A. (2008). Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. https://doi.org/10.3324/haematol.11575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.